RESUMO
Abstract Background: End-stage renal diseases patients have a high risk of postoperative nausea and vomiting (PONV), which is multifactorial and need acute attention after renal transplantation for a successful outcome in term of an uneventful postoperative period. The study was done to compare the efficacy of palonosetron and ondansetron in preventing early and late-onset PONV in live donor renal transplantation recipients (LDRT). Methods: The prospective randomized double-blinded study was done on 112 consecutive patients planned for live donor renal transplantation. Patients of both sexes in the age group of 18-60 years were randomly divided into two groups: Group O (Ondansetron) and Group P (Palonosetron) with 56 patients in each group by computer-generated randomization. The study drug was administered intravenously (IV) slowly over 30 seconds, one hour before extubation. Postoperatively, the patients were accessed for PONV at 6, 24, and 72 hours using the Visual Analogue Scale (VAS) nausea score and PONV intensity scale. Results: The incidence of PONV in the study was found to be 30.35%. There was significant difference in incidence of PONV between Group P and Group O at 6 hours (12.5% vs. 32.1%, p = 0.013) and 72 hours (1.8% vs. 33.9%, p < 0.001), but insignificant difference at 24 hours (1.8% vs. 10.7%, p = 0.113). VAS-nausea score was significantly lower in Group P as compared to Group O at a time point of 24 hours (45.54 ± 12.64 vs. 51.96 ± 14.70, p = 0.015) and 72 hours (39.11 ± 10.32 vs. 45.7 ± 15.12, p = 0.015). Conclusion: Palonosetron is clinically superior to ondansetron in preventing early and delayed onset postoperative nausea and vomiting in live-related renal transplant recipients.
RESUMO
The human chronic metabolic disease is predominantly associated with the disturbance in the lipid, proteins and nucleic acid biological balance due to the attack of free radicals generated from oxidative stress. Currently, the available synthetic antioxidants are synthesized by food industries are very effective and inexpensive but as chronic use, it exhibits many toxicological health effects like synthetic drugs. Hence, plant origin antioxidants gained increasing attention all over the world. In this regards, Olive tree (Olea europaea L.) belongs to Oleaceae family and its by-products such as olive leaves and olive oil are highly focused by many researcher due to its potential therapeutic effects in a reversal of various chronic diseases without any side effects. Oleuropein and Oleic acid are the major components in the olive by products and attributes olive as a holly natural remedy and also olive oil considered as a potential food ingredient in the Mediterranean diet. The fat content in olive fruits is higher than olive leaves. Whereas, the protein ratio is higher in olive leaves and more abundance of Oleuropein, which contributes major health benefits as compared to olive oil. Oleic acid with high MUFA ratio contributes to the major health benefits of olive oil to several human chronic diseases.